Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas

Robinson, Lary A.; Babacan, Nalân Akgül; Tanvetyanon, Tawee; Henderson-Jackson, Evita; Druta, Mihaela

doi:10.1016/j.jtcvs.2020.03.179

Cited by 14 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that R0 resection was a significant predictor of OS [7]. Similarly, some other studies found that R0 was a strong marker for OS [1,6,8,9]. In our series, R0 resection was achieved in 17 patients (85%).…”

Section: Discussionsupporting

confidence: 72%

“…Spraker et al [5] reported that the rate of lymph node invasion was 16%, and that lymph node invasion constituted a significant prognostic factor for OS. In other studies, the lymph node invasion rates were between 8% and 22.5% [7][8][9]. Our study showed no metastasis in the N2 station, and the rate of N1 invasion was 15%.…”

Section: Discussionsupporting

confidence: 54%

“…Generally, poor median and 5-year OS outcomes have been reported in related studies. Robinson et al [9] reported that the median OS was 39 months, and the 5-year OS was 28.7%. They emphasized that the OS was better in the surgical group [9].…”

Section: Discussionmentioning

confidence: 99%

“…Robinson et al [9] reported that the median OS was 39 months, and the 5-year OS was 28.7%. They emphasized that the OS was better in the surgical group [9]. Yamada et al [8] found that the 5-year OS was 50%, and significant prognostic factors were tumor diameter, stage, and grade and incomplete resection.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Analysis of Primary Pulmonary Malignant Mesenchymal Tumors Treated Surgically

et al. 2021

View full text Add to dashboard Cite

Background: Primary pulmonary malignant mesenchymal tumors are rare, constituting only 0.4% of all lung cancers. Since sarcomas are chemo/radio-resistant, surgical resection is the optimal treatment choice for patients with suitable medical conditions and tumor stage. In the present study, we analyzed the surgical outcomes and survival of primary pulmonary malignant mesenchymal tumors treated surgically. Methods: We retrospectively examined the records of patients with primary pulmonary malignant mesenchymal tumors who underwent surgical resection at our department between January 2010 and December 2020. Patient data were analyzed according to age, sex, tumor grade and stage, resection completeness, surgical type, and tumor histopathology. Results: Twenty patients were included in the study. There were 13 men (65%) and 7 women (35%). The median survival rate was 36 months (range, 19-53 months), and the 5-year overall survival rate was 37%. Unfavorable prognostic factors for overall survival included parietal pleural invasion (p=0.02), high tumor grade (p=0.02), advanced tumor stage (p=0.02), and extensive parenchymal resection (pneumonectomy and bilobectomy, p=0.01). The median length of disease-free survival was 31 months (interquartile range, 21-41 months), and the 5-year disease-free survival rate was 32%. The most unfavorable prognostic factors for recurrence were parietal pleural invasion (p=0.02), high tumor grade (p=0.01), and tumors requiring lung resection with chest wall resection (p=0.02). Conclusion:Primary malignant mesenchymal lung tumors are aggressive and have a high mortality rate. However, acceptable overall and disease-free survival rates can be obtained with surgical therapy.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionsupporting

confidence: 54%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Analysis of Primary Pulmonary Malignant Mesenchymal Tumors Treated Surgically

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In their manuscript, Robinson and colleagues 1 put forth a 20-year retrospective case series of 100 consecutive patients with primary pulmonary sarcomas (N ¼ 45) and carcinosarcomas (N ¼ 55), both of which represent rare tumors of the lung with an incidence less than 1%. By reputation, these tumors are known to be locally aggressive, often requiring more extensive lung resections, with poor responses to systemic therapy.…”

mentioning

confidence: 99%

Commentary: Sarcomas and sarcomatoid tumors of the lung…not your average lung cancers

Sihag

2021

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

Establishment of a staging system for visceral sarcoma

Wang,

Xu,

Fang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundVisceral sarcoma is a rare malignancy with a poor prognosis. However, there is no recommended prognostic staging system for the malignant disease.MethodWe analyzed the data of patients diagnosed with primary soft tissue sarcoma (STS) of the abdomen and thoracic visceral organs between 2006 and 2017 at our hospital. Prognostic factors (size, tumor grade, and lymph node metastasis) were analyzed in our cohort (n = 203) and the SEER validation cohort (n = 5826).ResultsTumor size, grade, and lymph node metastasis were important prognostic factors for visceral sarcoma in both our and the SEER cohorts. Based on these prognostic factors, we established a new staging system for visceral sarcoma, by which patients could be stratified into clinically meaningful and non‐overlapping stages in both our cohort and the SEER validation series. Moreover, the area under the curve (AUC) value of the staging system for 5‐year survival was 0.84 (95% CI: 0.78–0.89) in our series and 0.80 (95% CI: 0.79–0.81) in SEER series, respectively. In addition, compared with the widely used FIGO staging system for female genital sarcoma, the visceral sarcoma staging system could more effectively and reliably stratify patients into four different prognostic groups.ConclusionsThe visceral sarcoma staging system is applicable for STS of the abdomen and thoracic visceral organs and is better than the current FIGO staging system for female genital sarcoma and should be incorporated into the AJCC Cancer Staging Manual.

show abstract

Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas

Cited by 14 publications

References 19 publications

Prognostic Analysis of Primary Pulmonary Malignant Mesenchymal Tumors Treated Surgically

Prognostic Analysis of Primary Pulmonary Malignant Mesenchymal Tumors Treated Surgically

Commentary: Sarcomas and sarcomatoid tumors of the lung…not your average lung cancers

Establishment of a staging system for visceral sarcoma

Contact Info

Product

Resources

About